{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:31:03Z","timestamp":1790872263786,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/qai.0b013e31819ff102","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T12:33:55Z","timestamp":1242909235000},"page":"37-46","source":"Crossref","is-referenced-by-count":38,"title":["Response to Zidovudine\/Didanosine-Containing Combination Antiretroviral Therapy Among HIV-1 Subtype C-Infected Adults in Botswana: Two-Year Outcomes from a Randomized Clinical Trial"],"prefix":"10.1097","volume":"51","author":[{"given":"Hermann","family":"Bussmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C William","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Novitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Okezie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaka","family":"Muzenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tendani","family":"Gaolathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndwapi","family":"Ndwapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Mawoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Widenfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Musonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madisa","family":"Mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Makhema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Essex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"DeGruttola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"Marlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 3","key":"R1-7-20210131","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200317003-00002","article-title":"Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote dIvoire.","volume":"17","author":"Djomand","year":"2003","journal-title":"AIDS"},{"key":"R2-7-20210131","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00002030-200207050-00008","article-title":"The Senegalese governments highly active antiretroviral therapy initiative: an 18-month follow-up study.","volume":"16","author":"Laurent","year":"2002","journal-title":"AIDS"},{"key":"R3-7-20210131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0140-6736(02)09330-3","article-title":"Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients response, survival, and drug resistance.","volume":"360","author":"Weidle","year":"2002","journal-title":"Lancet"},{"key":"R4-7-20210131","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00002030-200404090-00006","article-title":"Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.","volume":"18","author":"Coetzee","year":"2004","journal-title":"AIDS"},{"key":"R5-7-20210131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.qai.0000159668.80207.5b","article-title":"Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.","volume":"40","author":"Wester","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-7-20210131","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(06)68580-2","article-title":"Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.","volume":"367","author":"Ferradini","year":"2006","journal-title":"Lancet"},{"key":"R7-7-20210131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.trstmh.2004.05.002","article-title":"Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model.","volume":"98","author":"Harries","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R8-7-20210131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.296.7.782","article-title":"Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.","volume":"296","author":"Stringer","year":"2006","journal-title":"JAMA"},{"key":"R9-7-20210131","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1057504","article-title":"Public health. HIV\/AIDS treatment for millions.","volume":"292","author":"Binswanger","year":"2001","journal-title":"Science"},{"key":"R10-7-20210131","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(02)09337-6","article-title":"Shadow on the continent: public health and HIV\/AIDS in Africa in the 21st century.","volume":"360","author":"De Cock","year":"2002","journal-title":"Lancet"},{"key":"R11-7-20210131","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1086\/431482","article-title":"Lessons learned from use of highly active antiretroviral therapy in Africa.","volume":"41","author":"Akileswaran","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R12-7-20210131","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1473-3099(02)00180-9","article-title":"AIDS control in sub-Saharan Africa-are more drugs and money the solution?","volume":"2","author":"Hanson","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"R13-7-20210131","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/QAD.0b013e3281900eb9","article-title":"Adherence to antiretroviral therapy in resource-limited settings: everything matters.","volume":"21","author":"Hawkins","year":"2007","journal-title":"AIDS"},{"key":"R14-7-20210131","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/00002030-200309050-00011","article-title":"High levels of adherence do not prevent accumulation of HIV drug resistance mutations.","volume":"17","author":"Bangsberg","year":"2003","journal-title":"AIDS"},{"key":"R15-7-20210131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(05)70327-3","article-title":"A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.","volume":"6","author":"Colebunders","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"R16-7-20210131","first-page":"148","article-title":"First-line antiretroviral therapy in Africa-how evidence-base are our recommendations?","volume":"7","author":"Colebunders","year":"2005","journal-title":"AIDS Rev"},{"key":"R17-7-20210131","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/506362","article-title":"The Antiretroviral Therapy Cohort Collaboration Correspondence. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.","volume":"194","author":"Egger","year":"2006","journal-title":"J Infect Dis"},{"key":"R18-7-20210131","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/506369","article-title":"Initial treatment of HIV infection: randomized trials with clinical end points are still needed.","volume":"194","author":"Hughes","year":"2006","journal-title":"J Infect Dis"},{"key":"R22-7-20210131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00126334-200312150-00007","article-title":"HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.","volume":"34","author":"Tenorio","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-7-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jama.293.7.817","article-title":"Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART.","volume":"293","author":"Nettles","year":"2005","journal-title":"JAMA"},{"key":"R24-7-20210131","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00126334-200110010-00001","article-title":"Transient relapses (blips) of plasma HIV RNA levels during HAART are associated with drug resistance.","volume":"28","author":"Cohen Stuart","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-7-20210131","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/QAI.0b013e3181568e3f","article-title":"Higher-than-expected rates of lactic acidosis among HAART-treated adults in Botswana: preliminary results from a large randomized clinical trial.","volume":"46","author":"Wester","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-7-20210131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(06)69152-6","article-title":"HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.","volume":"368","author":"May","year":"2006","journal-title":"Lancet"},{"key":"R27-7-20210131","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/aid.2006.0298","article-title":"The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV\/ddI-containing HAART in southern Africa.","volume":"23","author":"Novitsky","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R28-7-20210131","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.279.12.930","article-title":"A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.","volume":"279","author":"Montaner","year":"1998","journal-title":"JAMA"},{"key":"R29-7-20210131","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7326\/0003-4819-124-12-199606150-00001","article-title":"Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.","volume":"124","author":"DAquila","year":"1996","journal-title":"Ann Intern Med"},{"key":"R30-7-20210131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00042560-199812010-00004","article-title":"A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.","volume":"19","author":"Henry","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"Suppl 1","key":"R31-7-20210131","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.qai.0000137002.17634.4e","article-title":"The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in antiretroviral therapy.","volume":"37","author":"Young","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-7-20210131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/AAC.43.1.121","article-title":"Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.","volume":"43","author":"Zhou","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-7-20210131","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R35-7-20210131","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/01.aids.0000237365.18747.13","article-title":"National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?","volume":"20","author":"Beck","year":"2006","journal-title":"AIDS"},{"key":"R39-7-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":"Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"R40-7-20210131","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/QAI.0b013e318050d66c","article-title":"Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya.","volume":"45","author":"Hawkins","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R41-7-20210131","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350701200508","article-title":"Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.","volume":"12","author":"Boulle","year":"2007","journal-title":"Antivir Ther"},{"key":"R42-7-20210131","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/QAI.0b013e31802bf109","article-title":"Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.","volume":"44","author":"Sow","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R43-7-20210131","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e318033ffa1","article-title":"Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.","volume":"44","author":"Forna","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R44-7-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"issue":"Suppl 3","key":"R45-7-20210131","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00002030-200406003-00006","article-title":"Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa.","volume":"18","author":"Coetzee","year":"2004","journal-title":"AIDS"},{"key":"R46-7-20210131","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200306130-00011","article-title":"Adherence is not a barrier to successful antiretroviral therapy in South Africa.","volume":"17","author":"Orrell","year":"2003","journal-title":"AIDS"},{"issue":"Suppl 3","key":"R47-7-20210131","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/00002030-200317003-00014","article-title":"Adherence to HAART and its principal determinants in a cohort of Senegalese adults.","volume":"17","author":"Laniece","year":"2003","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200905010-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T18:43:44Z","timestamp":1710355424000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200905010-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31819ff102","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}